MOVE FORWARD WITH MYNX



MYNX CONTROL™
VASCULAR CLOSURE DEVICE

Cordis

MYNX CONTROL™
VASCULAR CLOSURE DEVICE

CLOSE WITH CONFIDENCE. LEAVE NOTHING BEHIND*.

MYNX CONTROL™ Vascular Closure Device features a redesigned, ergonomic handle to facilitate ease-of-use and predictable deployment.

The Science of Active Extravascular Sealing

MYNX CONTROL™ VCD is comprised of two configurations of polyethylene glycol (PEG), for durable hemostasis.

Proven PEG Material

- **SAFE** No foreign-body reaction or scar tissue formation[1]
- **SYNTHETIC** Non-thrombogenic[1]
- **HYDROLYTIC DEGRADATION** Fully resorbs through hydrolysis—no enzymatic breakdown[1]

Dual-mode Active Sealing

1 TIP



- Activated by body temperature and pH
- Interlocks with contours of the vessel by actively attaching to the artery, for secure mechanical closure

2 MYNX™ SEALANT COLUMN



- Expands to 3-4 times its original size on contact with blood and subcutaneous fluids, creating a matrix structure for clot formation
- Provides further support for the tip.

FULLY EXTRAVASCULAR CLOSURE



30 DAY RESORBABILITY*

*The sealant is resorbed by the body within 30 days.

Secure Extravascular Closure in a wide range of clinical scenarios

Clinically versatile, MYNX CONTROL™ VCD offers dependable closure with nothing left behind* —treats a wide range of patients and clinical scenarios.

Safe closure below the femoral **bifurcation**†[2]



No footplates, sutures, or metal implants to impede **reaccess**



Useful on **antegrade** punctures[3]

Balloon **visualization** verifies position

†Confirm vessel size is ≥ 5mm

SAFETY BY THE NUMBERS

MYNX CONTROL™ VCD has been clinically proven to reduce surgical complications, expedite recovery, shorten hospital stays, and increase patient comfort.[2-7‡]

Safety and Efficacy in Interventions

A single-center, multi-year comparative analysis involving **4,074** percutaneous coronary intervention (PCI) patients found MYNX CONTROL™ VCD to be equally safe and effective as Angio-Seal™, with no intra-arterial components left behind.[4]

Access-site bleeding and vascular injury[4]



Safety in Clinical Trials and Real-world Use

In a prospective multi-center, non-randomized clinical trial (n=190) MYNX™ Family of products demonstrated: [2,8]



In a real-world cohort of 432 patients undergoing coronary angiography, MYNX™ Family of products demonstrated: [5]

‡Time to discharge eligibility as compared to manual compression. MATRIX Clinical Trial (IDE# G030182). Data on file.

Reduced Risk and Severity of Complications

In a retrospective, single-center review of **11,006** cardiac and peripheral vascular procedures, MYNX™ Family of products was proven to reduce the risk and severity of surgical complications following catheterization, compared to Angio-Seal™ and manual compression.[6]

Rate of surgical repair[6]



- 10x fewer secondary surgeries than Angio-Seal™[6]
- 3x fewer secondary surgeries than manual compression[6]
- MYNX™ Family of products complications did not involve embolism or artery damage, worsening of peripheral vascular disease, or necessitate device removal[6]

Increased Patient Comfort

In a blinded, randomized clinical study, pain at closure and pain increase from baseline to close were significantly lower for MYNX™ Family of products than Angio-Seal™ Closure Device.[7]

Less pain than Angio-Seal™ Closure Device



MYNX CONTROL™
VASCULAR CLOSURE DEVICE

MADE FOR PREDICTABLE DEPLOYMENT. DESIGNED FOR EASE OF USE.

The next-generation MYNX CONTROL™ Vascular Closure Device (VCD) deployment system is purpose-designed to enhance safety and deliver reliable performance.



Tension Indicator

Provides visual confirmation of device position for proper sealant deployment

Ergonomic Handle

Facilitates ease of use for predictable deployment

Sheath Catch

Compatible with procedural sheath—eliminates the need for sheath exchanges§

Button #1

Deploys and compresses the sealant

Button #2

One-step balloon withdrawal

§ MYNX CONTROL™ VCD is incompatible with Medtronic Input® Introducer (11cm) sheaths, Cook Check-Flo® Performer® Introducer sheaths, and procedural sheaths longer than 12cm in effective length.

Procedure Steps

1. DEPLOY THE BALLOON



Achieve temporary hemostasis and position at the arteriotomy.

2. PLACE THE SEALANT



The MYNX CONTROL™ VCD tip securely adheres to the artery and MYNX™ Sealant fills the tissue tract.

3. REMOVE THE DEVICE



Platelets and blood cells collect inside the sealant's porous matrix.

4. FINAL RESULT

The sealant dissolves within 30 days leaving nothing behind but a healed artery.

CLOSES WITH SECURITY. LEAVES WITHOUT A TRACE*

MYNX CONTROL™ Vascular Closure Device (VCD) integrates dual-mode active sealing and resorbability with a next-generation delivery system to maximize predictability, safety, and ease of use.

SECURE CLOSURE

SAFETY AND PATIENT COMFORT

EASE OF USE

*The sealant is resorbed by the body within 30 days.

Ordering Information

The MYNX CONTROL™ VCD includes:

- MYNX CONTROL™ VCD including balloon catheter and integrated polyethylene glycol sealant
- 10ml locking syringe

SIZE	EMEA ORDER NUMBER
5F	MX5060E
6F/7F	MX6760E

To order the MYNX CONTROL™ VCD contact your local Cordis sales representative or customer service.

REFERENCES: 1. Scheinert D, Sievert H, Turco MA, et al. The safety and efficacy of an extravascular, water-soluble sealant for vascular closure: Initial clinical results for MYNX™. *Cathet Cardiovasc Intervent*. 2007 Oct;70:627-633. **2.** MYNX CONTROL™ Vascular Closure Device Instructions for Use. **3.** Pruski MJ Jr, Blachut AM, Konkolewska M, et al. MYNX™GRIP for closure of antegrade puncture after peripheral interventions with same-day discharge. *Vasc Endovasc Surg*. 2017 Feb;51(2):67-71. **4.** Baker NC, Escarcega RO, Lipinski MJ, et al. Active versus passive anchoring vascular closure devices following percutaneous coronary intervention: a safety and efficacy comparative analysis. *J Interv Cardiol*. 2016 Feb; 29(1): 108-112. **5.** Hutchings D, Hayat A, Karunakaran A, Malik N. Success, Safety, and Efficacy of the MYNX™ Femoral Closure Device in a Real-World Cohort: Single-Center Experience. *J Invasive Cardiol*. 2016 Mar;28(3): 104-108. **6.** Noor S, Meyers S, Curl R. Successful reduction of surgeries secondary to arterial access site complications: a retrospective review at a single center with an extravascular closure device. *Vasc Endovascular Surg*. 2010 Jul;44(5):345-349. **7.** Fargen KM, Hoh BL, Mocco J. A prospective randomized single-blind trial of patient comfort following vessel closure: extravascular synthetic sealant closure provides less pain than a self-tightening suture vascular compression device. *J NeuroInterv Surg*. 2011 Sep; 3(3): 219-223. **8.** MATRIX Clinical Trial (IDE# G030182). Data on file.

For Healthcare Professionals Only. Important information: Prior to use, refer to the Instructions for Use supplied with this device for indications, contraindications, suggested procedure, warnings and precautions. As part of its continuous product development policy, Cordis reserves the right to change product specifications without prior notification. Please contact your Cordis representative for additional product availability information. CORDIS, Cordis LOGO, MYNX and MYNX CONTROL are trademarks of Cordis and may be registered in the US and/or in other countries. All other marks are the property of their respective owners. © 2024 Cordis. All Rights Reserved. 100538826-3 09/2024

CE 2797

Cordis. GO BEYOND